Science ❯ Medical Research ❯ Clinical Trials

Drug Efficacy

Neurological Disorders Health Outcomes Preventive Medicine Long-acting Treatments Weight Loss Treatments GLP-1 Receptor Agonists Public Health Impacts GLP-1 Research Cardiovascular Disease Research HIV Research Public Health Alzheimer's Research HIV Treatment Innovations Safety Assessments GLP-1 Injections Side Effects of Medications Neuroscience Immunology Weight Loss Mechanisms AI in Research Ivermectin Studies Health Risks Cytosinicline RAS Mutations Statistical Significance

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

The result could change investor views on the value of Novartis' $12 billion Avidity acquisition by reducing confidence in its late‑stage neuromuscular bets and prompting a formal data review with regulators.

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Ivermectin Combo Prescriptions Jump After Mel Gibson Podcast, Study Finds

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Novartis Licenses Arrowhead’s RNAi Parkinson’s Drug in Deal Worth Up to $2.2 Billion

EU Regulator Recommends AstraZeneca’s Low-Carbon COPD Inhaler